Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prevention of contrast-induced nephropathy

    • 23 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Mizuno T, Takashima H, Maeda K, Asai K, Kuroda Y, Kosaka T, Kuhara Y, Kurita A, Wakida Y, Ito T.Low-dose administration of carperitide protect the renal function from contrast agent in patients with chronic kidney disease, through the reduction of the renal tubular stress. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P5582, 27 Aug 2011. Available from: URL: http://spo.escardio.org/abstractdetails.aspx?id=100808&;eevtid=48

    2. 2.

      Nawa T, Nishigaki K, Hattori A, Minatoguchi S.Nicorandil, a K-ATP channel opener, can prevent contrast-induced nephropathy and improve prognosis in patients with poor renal function undergoing percutaneous coronary intervention. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P5583, 27 Aug 2011. Available from: URL: http://spo.escardio.org/abstractdetails.aspx?id=100809&;eevtid=48

    3. 3.

      Gila LT, Rivera K, Gomez-Hospital JA, Roura G, Ferreiro JL, Maristany J, Sanchez-Elvira G, Jara P, Esplugas E, Cequier A.Impact of an intense regimen of nephroprotection in the incidence of contrast nephropathy after revascularization of coronary chronic total occlusions. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P5581, 27 Aug 2011. Available from: URL: http://spo.escardio.org/abstractdetails.aspx?id=100807&;eevtid=48

    4. 4.

      Brueck M, Cengiz H, Boening A.Comparison of N-acetylcysteine or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P1640, 27 Aug 2011. Available from: URL: http://spo.escardio.org/abstractdetails.aspx?id=97885&;eevtid=48

    5. 5.

      Huang S-S, Huang P-H, Wu T-C, Chen J-W, Lin S-J.Bilirubin protects against contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P5585, 27 Aug 2011. Available from: URL: http://spo.escardio.org/AbstractDetails.aspx?id=100811

    6. 6.

      Ha SJ, Kim JW, Kim MK, Yoo TK, Woo JS, Kim SJ, Kim WS, Kim W, Kim KS.Usefulness of statin pretreatment to prevent contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention in real world. ESC Congress 2011: Annual Congress of the European Society of Cardiology: abstr. P5584, 27 Aug 2011. Available from: URL: http://spo.escardio.org/abstractdetails.aspx?id=100810&;eevtid=48

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Prevention of contrast-induced nephropathy. React. Wkly. 1370, 3–4 (2011). https://doi.org/10.2165/00128415-201113700-00006

    Download citation

    Keywords

    • Statin
    • Percutaneous Coronary Intervention
    • Nicorandil
    • Chronic Total Occlusion
    • Acetylcysteine